4.5 Interaction with other medicinal products and other forms  of inter action 
 In vitro studie s indicate that  raltegravi r is not a substrate of cytochrome P450 (CYP) enzymes, doesnot inhibit CYP1A2, CYP2B6, CYP
2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not inhibit 
 UDP  glucuronosyltransferases (UGTs) 1A1 and 2B7, does not in duce CYP3A4  and does no t inhibit 
 P-glycoprotein -mediated transport. Based on
 these data, raltegrav ir is not expected to aff ect thepharmacokinetics of medicinal products that are substrates of  these enzymes or P
-glycopr otein.Based on in vitro and in vivo studies, raltegravir is eliminated mainly by metabolism via a 
 UGT1A1 -mediated glucuronidation pathway.Considerable inter - and intra-individual variability was observed in the pharmacokinetics ofraltegravir .Ef f ect of  raltegravir on
 the pharma cokinetic s of other medicinal products 
 In interaction studies, raltegravir did not have a clinically meaningful ef f ect on the pharmacokineticsof  etravirine, maraviroc, tenof ovir  disoproxil fumarate , hormonal contraceptives, methadone,midazola m or boceprevir. In some studies, co
-admi nistration of  raltegravir  with darunavir resulted in a modest decrease indarunavir plasma concentrations
; the mechanism f or this eff ect is
 unknown. However, the ef f ect ofraltegravir on darunavir
 plasma concentrations does not appea r to be clinically meaningful.6Effect of other medicinal products on the pharmacokinetics of raltegravir 
 Given that raltegravir
 is metabolised primarily via UGT
1A1, caution should be used whenco-administering raltegr avir with strong inducers of UGT1A1 (e.g
., rifampicin). Rifampicin reducesplasma leve ls of  raltegravir; the impact on the ef f icacy of raltegravir is unknown. However
, ifco-administration with rifampicin is unavoidable,
 a doubling of  the dose of  raltegrav ir can beconside red in adults. There  are no data to guide co-administration of ralteg ravir with rifampicin inpatients below 18
 years of  age (see section  4.4). The i mpact of  other strong inducers of
 drugmetabolizing  enzymes, such as phenytoin and phenobarbital, on UGT1A1
 is unknown . Less po tentinducers (e.g., efavirenz, nevirapine, etravirine, rif abutin, glucocorticoids, St. John's wort,pioglitazone) may be used with the recommended dose of ralteg ravir.Co-administra tion of  raltegra vir with medicinal products that are known to be potent U GT1A1inhibitors (e.g.,
 atazanavir) may increase plasma levels of raltegravir. Less potent UGT1A1 inhibitors(e
.g., indinavir, saquinavir) may also increase plasma levels of  raltegravir, but to a lesser extentcompared with atazanavir. In addition, tenof ov ir disoproxil fumarate may increase plasma levels
 ofraltegravir, however, the mechanism f or this effect is unknown (see Table
 1)
. From the clinical trials, alarge proportion of patients used atazanavir and / or tenofovir disoproxil f u marate, both agents thatresult in increases in raltegravir plasma levels, in the optimised background regimens. The safetyprofile observed in patients who used atazanavir and / or tenof ovir  disoproxil f umarate  was gen erallysimilar to th e safety prof ile of patients who did not use these agents. Theref ore, no dose adjustment isrequired.Co-adminis tration of  raltegravir  with antacids containing divalent metal cations may reduce raltegravirabsorption by
 chelation, resulting in a decrease of  raltegravir plasma levels. Taking an aluminium andmagnes ium antacid within 
6 hours  of raltegravir administration signif icantly decreased raltegravirplasma levels
. Theref ore , co-administration of
 raltegravir  with alu minium and/or magnesiumcontaining a ntacids is not recommended. Co-admini stration of  raltegravir  with a calcium carbonateantacid decreased raltegravir plasma levels; however, this interaction is not considered cl inicallymeaningful. Theref ore, when ralteg ravir is co-administered with calcium carbonate containingantacids no do se adjustment is requir ed.Co-administration of raltegravir with other agents that increase gastric p 
 H (e.g., omeprazole andf amotidine) may increase the rate of
 raltegravir absorption and result in
 increased plasma levels ofraltegrav ir (see Table 1). Sa f ety profiles in the subgroup of patients in Phase III trials taking protonpump inhibitors or H2 antagonists were comparable with those who
 were not taking these
 antacids.Theref ore , no dose adjustment is required with
 use of proton pump inhibitors or H2 antagonists.All inter action studies were perf ormed in adults.Table  1Pharmacokinetic Interaction Data 
 Medicinal products by therapeuticarea 
 Interaction(mechanism, if  known)Recommendationsconcerning co-adminis tration 
 ANTI -RET ROVIRALProtease in hibitors (PI)atazanav ir /ritonavir(raltegravir
 400 mg Twice Daily)raltegravir AUC 
 41 %raltegravir C12hr  77 %raltegravi r Cmax  24 %(UGT1A1 inhibition
)No dose adjustment requiredf or raltegravir .7Medicinal products by therapeuticarea 
 Interaction(mechanism, if  known)Recommendationsconcerning co-adminis trationtipranav ir /ritonavir(raltegravir 400 mg Twi ce Daily)raltegravir AUC  24 %raltegravir C
12hr  55 %raltegravir C max  18 %(UGT1A1 induction)No dose adjustment requiredf or raltegravir .Non-nucleoside reverse transcriptase inhibitors (NNRTIs)efavirenz  (raltegravir 400  mg Single Dose) 
 raltegravir AUC  36 %raltegravir C 12hr  21 %raltegravir Cmax  36 %(UGT1A1  induction)No dose ad justment requiredf or raltegrav ir.etrav irine(raltegravir 400
 mg Twice Daily)raltegravir AUC 
 10 %raltegravir C
12hr  34 %raltegra vir Cmax  11 %(UGT1A1 induction)etravi rine AUC  10 %etravirine  C12hr  17 %etravirine Cmax  4 %No dose adjustment requiredf or raltegravir  or etraviri ne.Nucleoside/tide reverse transcriptase
 inhibitorstenofovir  disoproxil fumara te (raltegrav ir 400 mg T wice Dail y) raltegravir AUC 
 49 %raltegravir C
12hr  3 %raltegravir Cmax ↑ 64 %(mechanism of  interactionunknown)tenof ovir AUC 
 10 %tenof ovi r C24hr  13 %tenof ovir C max ↓ 23 %No dose adjustment requiredf or raltegravir  or tenof ovirdisop roxil f umarate.CCR5 inhibitorsmarav iroc(raltegravir 400
 mg Twice Daily)raltegravir AUC   37 %raltegravir C
12hr  28 %raltegravir C max  33 %(mechanism of  interactionunknown)maraviroc AUC 
 14 %maraviro c C 12hr  10 %maraviroc  Cmax ↓ 21 %No dose adjustment requiredf or raltegravir  or maraviroc.HCV ANTIVIRALSNS3/4 A prot ease inhib itors (PI)boceprevir(raltegravir  400 mg Single Dose)raltegra vir AUC  4 %raltegravir C
12hr  25 %raltegravir Cmax  11 %(mechanism of  interactionunknown)No dose adjustment requiredf or raltegra vir or boceprevir.8Medicinal products by therapeuticarea 
 Interaction(mechanism, if  known)Recommendationsconcerning co-adminis tration 
 ANTIMICROBIALSAntimyc obacterialrifampicin(raltegra vir 400 mg Single Dose)raltegr avir AUC  40 %raltegravir C
12hr  61 %raltegravir Cmax  38 %(UGT1A1 induction)Rif ampicin reduces plasmalevels of  raltegravir . Ifco-administration withrif ampicin is unavoidable, adoub ling of  th e dose ofraltegravir  can be consid ered(see section
 4.4).SEDA TIVEmidazolam(raltegravir  400 mg Twice Daily)midazolam AUC 
 8 %midazolam Cmax ↑ 3 %No dosa ge adjustment requiredf or raltegravir  or midazolam.These results indicate thatraltegravir  is not an inducer orinhibitor of  CYP3A4, andralteg ravir is th us notanticipated to af f ect thepharmacokinetics of medicinalproducts which are CYP3A4substrates .METAL CATION ANTACIDSalumin ium and magnesiumhydroxide antacid(raltegra vir 40 0 mg Twice  Daily)raltegravir AUC  49 %raltegravir C 12 hr  63 %raltegr avir C max  44 %
2 hours bef ore raltegravirraltegravir AUC 
 51 %raltegravir C
12 hr  56 %raltegravir C max  51 %
2 hours af ter raltegravirraltegravir AUC 
 30 %raltegra vir C 12 hr  57 %raltegravir Cmax  24 %
6 hours bef ore raltegravirraltegravi r AUC  13 %raltegravir C
12 hr  50 %raltegravir Cmax  10 %
6 hours af ter raltegravirraltegrav ir AUC  11 %raltegravir C
12 hr  49 %raltegravir C max  10 %(chelation of  meta l cation s)Aluminium  and magnesiumcontaining  antacids reduceraltegravir plasma levels.Co-administration ofraltegravir  with aluminiumand/or magnesium containingantacids  is not recommended.calcium carbonate antacid(raltegravir 400
 mg Twice Daily)raltegravi r AUC  55 %raltegrav ir C12 hr  32 %raltegravir Cmax  52 %(chelation of  metal cations)No dose adjustment requiredf or raltegravir .9Medicinal products by therapeuticarea 
 Interaction(mechanism, if  known)Recommendationsconcerning co-adminis tration 
 Other METAL
 CATIONIron salts Expected :Raltegravir AUC (chelation of  metal cations)Given simultaneously iron saltsare expected to
 reduceraltegravir plasma levels
;taking iron salts at least twohours from the administrationof  raltegravir may allow tolimit this ef f ect.H2 BLOCKERS AND PROTON PUMP  INHIB ITORSomeprazole  (raltegravir 400
 mg Twice  Daily ) raltegravir AUC ↑  37 %raltegrav ir C12 hr ↑ 24 %raltegravir Cmax ↑ 51 %(increased solubility)No dose adjustment requiredf or raltegravir .famotidine(raltegravir 400
 mg Twice Daily)raltegravir AUC
 ↑ 44 %raltegravir C
12 hr ↑ 6 %raltegravir Cmax ↑ 60 %(increased solubility)No dose adjustment requiredf or raltegravir .HORMONAL CONTRACEPTIVESEthinyl Estradiol 
 Norelgestromin(raltegravir 400
 mg Twice Daily)Ethinyl Estradiol AUC 
 2 %Ethinyl Es tradiol C max ↑ 6 %Norelgestromin AUC ↑  14 %Norelgestromin Cmax ↑ 29 %No dosage a djustment r equiredf or raltegravir  or hormonalcontra ceptives (e strogen -and/or progesterone
-based).OPIOID ANALGESICSmethadone(raltegravir 400
 mg Twice Daily)methadone  AUC ↔  methadone Cmax ↔ No dose adjustment requiredf or raltegravir  or me thadone.
